iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Free Report)’s share price hit a new 52-week low during trading on Monday after Truist Financial lowered their price target on the stock from $117.00 to $80.00. Truist Financial currently has a buy rating on the stock. iRhythm Technologies traded as low as $56.40 and last traded at $57.66, with a volume of 23516 shares. The stock had previously closed at $57.07.
A number of other equities research analysts have also weighed in on IRTC. Citigroup cut their price objective on iRhythm Technologies from $135.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, August 22nd. Oppenheimer reduced their price objective on iRhythm Technologies from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Canaccord Genuity Group increased their target price on shares of iRhythm Technologies from $122.00 to $137.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Robert W. Baird dropped their target price on shares of iRhythm Technologies from $120.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Needham & Company LLC decreased their target price on shares of iRhythm Technologies from $138.00 to $119.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, iRhythm Technologies has an average rating of “Moderate Buy” and a consensus target price of $112.40.
Check Out Our Latest Analysis on iRhythm Technologies
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in IRTC. Sei Investments Co. lifted its position in shares of iRhythm Technologies by 7.0% in the first quarter. Sei Investments Co. now owns 235,361 shares of the company’s stock worth $27,302,000 after buying an additional 15,381 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of iRhythm Technologies during the 1st quarter worth about $1,925,000. Capstone Investment Advisors LLC bought a new position in shares of iRhythm Technologies in the first quarter valued at approximately $1,078,000. Assenagon Asset Management S.A. lifted its position in iRhythm Technologies by 361.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 48,962 shares of the company’s stock worth $5,270,000 after buying an additional 38,344 shares in the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in shares of iRhythm Technologies during the first quarter valued at approximately $58,311,000.
iRhythm Technologies Price Performance
The company has a fifty day simple moving average of $68.97 and a two-hundred day simple moving average of $89.33. The stock has a market capitalization of $1.79 billion, a P/E ratio of -13.85 and a beta of 1.22. The company has a current ratio of 6.92, a quick ratio of 6.76 and a debt-to-equity ratio of 6.50.
iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.28. iRhythm Technologies had a negative net margin of 24.50% and a negative return on equity of 84.14%. The firm had revenue of $148.05 million during the quarter, compared to analyst estimates of $146.15 million. During the same period in the prior year, the business earned ($0.61) EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. Sell-side analysts expect that iRhythm Technologies, Inc. will post -2.66 EPS for the current fiscal year.
iRhythm Technologies Company Profile
iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Read More
- Five stocks we like better than iRhythm Technologies
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Investing In Preferred Stock vs. Common Stock
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- How to Invest in Insurance Companies: A Guide
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.